US Patent

US10436802 — Methods for treating spinal muscular atrophy

Method of Use · Assigned to Biogen MA Inc · Expires 2035-09-11 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating spinal muscular atrophy by modulating the splicing of SMN2 mRNA in a subject.

USPTO Abstract

Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy. Also provided are kits for detecting the amount of SMN protein in a sample of cerebrospinal fluid.

Drugs covered by this patent

nusinersen-sodium (NUSINERSEN SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2094`	—	nusinersen-sodium

Patent Metadata

Patent number: US10436802
Jurisdiction: US
Classification: Method of Use
Expires: 2035-09-11
Drug substance claim: No
Drug product claim: No
Assignee: Biogen MA Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.